Lymphoma Treatment Market
Lymphoma Treatment Market Size, Share & Trends Analysis Report by Type (Hodgkin and Non-Hodgkin), By Therapy Type (Radiation therapy, Chemotherapy, and Others), By Drug Type (Adcetris, Rituxan/MabThera, Imbruvica, Keytruda, Revlimid, and Others), Forecast 2019-2025
The global Lymphoma treatment market is anticipated to grow at a CAGR of around 8% during the forecast period. The Lymphoma treatment consists of the use of various therapies such as biologic therapy, antibody therapy, chemotherapy, radioimmunotherapy, and radiation therapy. In some cases, these therapies are combined for several patients, for instance, chemotherapy and radiation therapy combination. Additionally, stem cell transplantation, Steroids, and Surgery are also used as the form of treatment for Lymphoma. Stem cell transplant can aid to restore damaged bone marrow following high dose chemotherapy or radiation therapy.
The recent rise in non-Hodgkin types of Lymphoma due to factors such as autoimmune disease, whose chronic irritation can be cancer-causing is driving the Lymphoma treatment market. According to Leukemia & Lymphoma Society, in 2019, 82,310 new cases of Lymphoma were expected to be diagnosed in the US, which included 8,110 cases of Hodgkin Lymphoma and 74,200 cases of Non-Hodgkin Lymphoma. With the rise in incidence, the pharmaceutical companies operating in the oncology landscape are adopting strategies such as collaborations and acquisitions for strengthening their position in the Lymphoma treatment market.
Segmental Outlook
The global Lymphoma treatment market is segmented on the basis of type, therapy type, and drug type. Based on type, the market is bifurcated into Hodgkin and Non-Hodgkin Lymphoma. Based on therapy type, the market is sub-segmented into radiation therapy, chemotherapy, and others. Further, on the basis of the drug type, the market is sub-segmented into adcetris, rituxan/mabthera, imbruvica, keytruda, revlimid, and others such as opdivo.
Global Lymphoma Treatment Market Share by Therapy Type, 2018 (%)
Chemotherapy will be the largest segment by Therapy Type
The chemotherapy segment is anticipated to hold a significant share in the Lymphoma treatment market owing to its easy availability and increasing adoption across the globe. Chemotherapy is the first line of treatment for the majority of patients diagnosed with the Hodgkin Lymphoma. The availability of various paths to take chemo such as orally (by mouth), intravenously (into a vein), and intrathecally (into the fluid surrounding the brain and spinal cord) is anticipated to increase the chemotherapy segment demand in the Lymphoma treatment market.
Regional Outlooks
The global Lymphoma treatment market is further segmented based on geography including North America, Europe, Asia-Pacific and Rest of the World. North America is estimated to hold the largest market share in the Lymphoma treatment during the forecast period owing to the well-developed healthcare structure in the region coupled with the increasing number of patients diagnosed with Lymphoma in the region. According to the Leukemia & Lymphoma Society, in 2019, there were expected to be 82,310 new cases of Lymphoma diagnosed in the US alone.
Global Lymphoma Treatment Market Growth, by Region 2019-2025
Asia-Pacific will Augment with the Fastest Growth Rate in the Lymphoma Treatment Market
Asia-Pacific is anticipated to grow at the fastest rate in the Lymphoma treatment market. The major economies contributing to the growth of the Asia-Pacific Lymphoma treatment market include China, Japan, and India. In addition, the rise in healthcare expenditure, high unmet clinical needs, and increasing awareness regarding various treatment options coupled with the availability of effective treatment in economies such as China & South Korea further give a boost to the regional growth of the market.
Market Players Outlook
Some of the key players operating inthe global Lymphoma treatment market include Pfizer Inc., Johnson & Johnson Services Inc., Celgene Corp., Bristol Myers Squibb Co., Takeda Pharmaceutical Co. Ltd., GlaxoSmithKline PLC, Novartis International AG, Sanofi, Seattle Genetics Inc., Teva Pharmaceutical Industries Ltd., and others. The market players are considerably contributing to market growth by adopting various strategies to stay competitive in the market.
The Report Covers
- Market value data analysis of 2018 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Lymphoma treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Bristol-Myers Squibb Co
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Celgene Corp.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Pfizer Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Johnson & Johnson Services Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Takeda Pharmaceutical Co.Ltd.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. Lymphoma treatment Market by Type
5.1.1. Hodgkin
5.1.2. Non-Hodgkin
5.2. Lymphoma treatment Market by Therapy Type
5.2.1. Radiation therapy
5.2.2. Chemotherapy
5.2.3. Others (Monoclonal Antibody Therapy)
5.3. Lymphoma treatment Market by Drug Type
5.3.1. Adcetris
5.3.2. Rituxan/MabThera
5.3.3. Imbruvica
5.3.4. Keytruda
5.3.5. Revlimid
5.3.6. Others (Opdivo)
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AbbVie Inc.
7.2. AeternaZentaris Inc.
7.3. AstraZeneca PLC
7.4. Bayer AG
7.5. Bristol Myers Squibb Co.
7.6. Cadila Pharmaceuticals Ltd.
7.7. Celgene Corp.
7.8. Eli Lilly and Co.
7.9. Epizyme, Inc.
7.10. F. Hoffmann-La Roche Ltd.
7.11. GlaxoSmithKline PLC
7.12. Johnson & Johnson Services Inc.
7.13. Merck & Co., Inc.
7.14. Novartis International AG
7.15. Pfizer Inc.
7.16. Sanofi SA
7.17. Seattle Genetics, Inc.
7.18. Spectrum Pharmaceuticals, Inc.
7.19. Takeda Pharmaceutical Co.Ltd.
7.20. Teva Pharmaceutical Industries Ltd.
1. GLOBAL LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
2. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
4. GLOBAL LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2018-2025 ($ MILLION)
5. GLOBAL RADIATION THERAPY FOR LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
6. GLOBAL CHEMOTHERAPY FOR LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
7. GLOBAL OTHER THERAPY FOR LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
8. GLOBAL LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2018-2025 ($ MILLION)
9. GLOBAL ADCETRIS FOR LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
10. GLOBAL RITUXAN/MABTHERA FOR LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
11. GLOBAL IMBRUVICA FOR LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
12. GLOBAL KEYTRUDA FOR LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
13. GLOBAL REVLIMID FOR LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
14. GLOBAL OTHER DRUGS FOR LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
15. GLOBAL LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
16. NORTH AMERICAN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
17. NORTH AMERICAN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
18. NORTH AMERICAN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2018-2025 ($ MILLION)
19. NORTH AMERICAN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2018-2025 ($ MILLION)
20. EUROPEAN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
21. EUROPEAN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
22. EUROPEAN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2018-2025 ($ MILLION)
23. EUROPEAN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2018-2025 ($ MILLION)
24. ASIA-PACIFIC LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
25. ASIA-PACIFIC LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
26. ASIA-PACIFIC LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2018-2025 ($ MILLION)
27. ASIA-PACIFIC LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2018-2025 ($ MILLION)
28. REST OF THE WORLD LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
29. REST OF THE WORLD LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2018-2025 ($ MILLION)
30. REST OF THE WORLD LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2018-2025 ($ MILLION)
1. GLOBAL LYMPHOMA TREATMENT MARKET SHARE BY TYPE, 2018 VS 2025 (%)
2. GLOBAL LYMPHOMA TREATMENT MARKET SHARE BY THERAPY TYPE, 2018 VS 2025 (%)
3. GLOBAL LYMPHOMA TREATMENT MARKET SHARE BY DRUG TYPE, 2018 VS 2025 (%)
4. GLOBAL LYMPHOMA TREATMENT MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
5. US LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
6. CANADA LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
7. UK LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
8. FRANCE LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
9. GERMANY LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
10. ITALY LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
11. SPAIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
12. ROE LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
13. INDIA LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
14. CHINA LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
15. JAPAN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
16. REST OF ASIA-PACIFIC LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
17. REST OF THE WORLD LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
